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The protective immune response generated by a commercial monovalent inactivated vaccine against bluetongue virus serotype 1
(BTV1) was studied. Five sheep were vaccinated, boost-vaccinated, and then challenged against BTV1 ALG/2006. RT-PCR did not
detect viremia at any time during the experiment. Except a temperature increase observed after the initial and boost vaccinations,
noclinicalsignsorlesionswereobserved.AspeciﬁcandprotectiveantibodyresponsecheckedbyELISAwasinducedaftervaccina-
tion and boost vaccination. This speciﬁc antibody response was associated with a signiﬁcant increase in B lymphocytes conﬁrmed
by ﬂow cytometry, while signiﬁcant increases were not observed in T lymphocyte subpopulations (CD4+,C D 8 +, and WC1+),
CD25+ regulatory cells, or CD14+ monocytes. After challenge with BTV1, the antibody response was much higher than during the
boost vaccination period, and it was associated with a signiﬁcant increase in B lymphocytes, CD14+ monocytes, CD25+ regulatory
cells, and CD8+ cytotoxic T lymphocytes.
1.Introduction
Bluetongue virus (BTV), a member of the Orbivirus genus in
the Reoviridae family [1], shows considerable genetic and
antigenic variability, with at least 25 diﬀerent serotypes char-
acterized to date [2, 3]. These serotypes do not confer cross-
protective immunity, which means that speciﬁc vaccines
must be developed for each serotype [4].
Vaccination has proven very eﬀective in BTV control and
eradication strategies [5, 6]. A wide range of vaccines, based
on either inactivated or modiﬁed live virus, are available
against diﬀerent BTV serotypes [7]. Inactivated vaccines are
considered safer than vaccines based on modiﬁed live virus
because they do not allow the possibility of viral replication.
Therefore, they are useful for avoiding virus circulation
amongsusceptiblespecies[8,9].Indeed,inactivatedvaccines
havealreadybeenusedsuccessfullyinﬁeldtrials,andtheyare
the vaccines most recommended by EU authorities [8, 10].
Several inactivated BTV vaccines have been shown to
confer protection mainly by inducing production of neutral-
izing antibodies [11–14]. These antibodies protect primarily
against homologous serotypes, and they appear ineﬀective
at cross-protecting against heterologous serotypes [15, 16].
Some studies reveal that cell-mediated immunity could play
an important role [17] when vaccinating with individual
antigens [18], or concretely just in some sheep [19]. Also,
inactivated vaccines have been shown to protect against BTV
in the absence of neutralizing antibodies [4, 20] ,b u ti ti sw e l l
known that the main eﬀective response against BT is capable
to generate neutralizing antibodies [11].
Evaluating the cell-mediated immunity in animals vac-
c i n a t e da g a i n s tB T Vc o u l dp r o v i d ev a l u a b l ei n f o r m a t i o nf o r2 The Scientiﬁc World Journal
Table 1: Antibodies used to analyze PBMC populations by ﬂow cytometry.
Primary and
secondary
antibodies
Speciﬁcity Ig isotype Amount per
tube (μg) Source Reference
Anti-sheep B
lymphocytes B lymphocytes IgM 2 VMRD BAQ44A
Anti-sheep CD4 T helper lymphocytes IgG1 2 VMRD 17D1
Anti-sheep CD8 Cytotoxic T lymphocytes IgG1 2 VMRD CACT80C
Anti-sheep WC1 γδ subset of T lymphocytes IgG1 2 VMRD IL-A29
Anti-sheep CD25 IL-2 receptor α-chain IgG1 2 VMRD CACT116A
Anti-sheep CD14 Monocytes IgG1 2 VMRD CAM36A
FITC-conjugated
anti-mouse IgG1
(γ1)
Mouse IgG1 (γ1) — 0.4 Invitrogen P-21129
PE-conjugated
anti-mouse IgM Mouse IgM — 0.4 Sigma-Aldrich F-9259
assessing and improving the eﬃcacy of BTV vaccines. To that
end, the present study aimed to examine, in vivo, the cellular
and humoral immune response generated by a commercial
monovalent, inactivated vaccine against BTV serotype 1 in
Merino sheep.
2. MaterialsandMethods
All procedures were carried out in accordance with the Code
of Practice for Housing and Care of Animals Used in Scienti-
ﬁc Procedures, approved by the European Economic Com-
munity in 1986 (86/609/EEC) and amended by European
Commission Directive 2003/65/EC. The procedures were
also approved by the Animal Experimental Committee of
Complutense University of Madrid.
2.1. Animals. Five female Merino sheep of 9-10 months old
and negative for antigens or antibodies against BTV were
housed in Biosafety Level 3 facilities (VISAVET, Complu-
tense University of Madrid).
2.2. Vaccine. Ac o m m e r c i a li n a c t i v a t e dv a c c i n ea g a i n s tB T V
serotype 1 was used (Zulvac1, Fort Dodge Veterinaria SA).
Theactivecomponentperdose(2mL)wasBTV-1/ALG2006/
01 E1 ≥ 106.4 TCID50. This vaccine contains adjuvants such
as Quillaia bark, with the primary adjuvant being hydrated
aluminum hydroxide.
2.3. Vaccination, Boost Vaccination, and BTV Challenge. Vac-
cination was carried out SC on day 0 of the experiment.
Booster vaccination was performed by the same route on day
20.Inbothcases,thevaccinedosewas2mLasrecommended
by manufacturer. On day 48, all animals were challenged
with 1mL of BTV1 ALG/2006 at a virus title of 1.9 × 106
TCID50 in BHK cells. The challenge inoculum contained
1.9×106 TCID50 (kindlyprovidedbyCISA-INIA),anditwas
administered intravenously into the jugular vein. On day 68,
animals were euthanized.
2.4. Temperature Monitoring, Clinical Survey, and Necropsy.
Rectal temperature was measured on day 0 prior to vaccina-
t i o n ,a sw e l la so nv a r i o u sd a y su n t i lt h ee n do ft h et r i a lo n
day 68. On each of these occasions, clinical signs were scored
using the system described by Perrin et al. [21].
2.5. Sample Collection for Serology and BTV RNA Extraction.
Serum samples were collected on day 0 prior to vaccination,
as well as on days 3, 14, 16, 20, 21, 23, 26, 35, 42, 48, 51, 53,
54,57,58,61,62,and68.Sampleswereanalyzedbyadouble-
recognition ELISA (Ingezim BTV DR 12.BTV.K0, Ingenasa)
according to the manufacturer’s instructions. Antibody res-
ponse was measured as optical density.
Samples of EDTA blood were collected on day 0 prior to
vaccination, as well as on days 3, 20, 21, 23, 42, 48, 51, 53, 54,
57, 58, 61, 62 and 68. RNA was extracted from the samples
using the NucleoSpin RNA II kit (Macherey-Nagel). The
presence of BTV RNA was assessed using real-time RT-PCR
(RT-qPCR) targeting BTV segment 5. Brieﬂy, this RT-qPCR
was able to detect up to 100 RNA copies. The relationship
between the Ct and the copy number was linear between 17
and 33 cycles, which correspond to 1 × 108 and 1 × 103
copies, respectively. The RT-qPCR had an eﬃciency of 96%,
and it was associated with an R2 of 0.99. The RT-qPCR was
able to detect the mRNA in all of the 128 biological sam-
ples from sheep, goats, and cattle tested [22]. This could be
supposedasahighsensitivitycloseto100%.Inourstudy,the
negative controls were not template controls, while positive
controlswheresamplefromexperimentallyinfectedanimals,
and their Cts were between 20 and 25.
2.6. Flow Cytometry Analysis of Peripheral Blood Mononuclear
Cells. E D T Ab l o o ds a m p l e sw e r ec o l l e c t e do nd a y0p r i o rt o
vaccination, as well as on days 3, 14, 16, 20, 21, 23, 26, 35, 42,
48, 51, 53, 54, 57, 58, 61, 62, and 68. Flow cytometryusing an
FACS scan cytometer (Becton Dickinson) was used to detect
diﬀerent populations of peripheral blood mononuclear cells
(PBMCs) (Table 1).The Scientiﬁc World Journal 3
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Figure 1: (a) Antibody response in serum samples (mean optical density ± SD) measured by ELISA during the experiment. The threshold
below which a response was considered negative was deﬁned as 15% of the positive control optical density. Thus, samples with an optical
density > 0.252 were considered positive. The mean value after boost vaccination was signiﬁcantly diﬀerent from that after challenge (∗∗P ≤
0.05; Mann-Whitney U test for nonparametric distributions). (b) Individual measurements of antibody response. Abbreviations: V, day of
ﬁrst vaccination; DFV, day after ﬁrst vaccination; BV, day of boost vaccination; C, day of challenge.
2.7. Statistical Analysis. Data were analyzed using GraphPad
InStat 3.0 and IBM SPSS Statistics 19. Percentages of
PBMCsubpopulations(CD4+,CD8 +,W C1 +,CD25 +,Blym-
phocytes,andCD14+)arereportedasmean ±standarddevi-
ation (SD). Diﬀerences between the percentages of PBMC
populations at diﬀerent times and the values prior to vaccin-
a t i o no nd a y0w e r ea n a l y z e db yr e p e a t e d - m e a s u r e sA N O V A
with the Huynh-Feldt correction.
Optical density results from ELISA testing of serum sam-
ples are reported as mean ± SD. Diﬀerences among mean
optical density values after vaccination (days 0–20), after
boostvaccination(days21–48),andafterchallenge(days51–
68) were analyzed using the Mann-Whitney U test for non-
parametric distributions.
For all comparisons, diﬀerences for which P < 0.05 were
considered signiﬁcant.
3. Results
3.1. Temperature, Clinical Signs, and Lesions. Hyperthermia
(rectal temperature higher than 40◦C) was detected in three
sheep on day 1 after vaccination and in three sheep on day 21
after boost vaccination. After challenge, however, no increase
in temperature was detected in any animal.
No BTV clinical signs were observed during the experi-
ment. Moreover, necropsy failed to detect gross lesions char-
acteristic of BTV infection. Histopathology conﬁrmed the
absence of microscopic lesions characteristic of BTV.
3.2. Determination of Antibody Response by ELISA. As p e c i ﬁ c
antibody responseagainstBTVwasdetectedin allvaccinated
sheep from day 14 through the end of the experiment
(Figures 1(a) and 1(b)). Antibody levels peaked on day 14,
decreasing moderately thereafter. Antibody levels began to
riseagainfromday26,andthelevelsremainedrelativelycon-
stant until day 51. From that point until day 62, the levels
increased again, showing a slight decrease only in the ﬁnal
stage of the study.
Mean values of antibody response were compared for the
periodsaftervaccination(days0–20), afterboostvaccination
(days 21–48), and after challenge (days 51–68). No signiﬁ-
cant diﬀerences were observed between antibody levels after
vaccination (0.67±0.55) and after boost vaccination (0.88±
0.1). After challenge, however, the antibody level increased
signiﬁcantly to 1.04 ±0.12 (Figure 1(a)).
3.3. BTV RNA Detection by RT-PCR. N ov i r a lg e n o m ew a s
detected in the animals at any time in the study.
3.4. Analysis of PBMC Populations
3.4.1. CD4+. CD4+ T lymphocytes represented 32.87% of
PBMC before vaccination. Between days 14 and 21, the pro-
portion of CD4+ cells signiﬁcantly declined, with the mini-
mum value of 21.7% occurring on day 14 (Figures 2(a) and
2(b)). Subsequently, the proportion returned to its prevacci-
nation level. After challenge, the level decreased signiﬁcantly
againbetweendays51and53,reaching22.7%onday53.The
levelthenreturnedtoprevaccinationvaluesfortherestofthe
trial.
3.4.2. CD8+. The mean percentage of CD8+ Tl y m p h o c y t e s
prior to vaccination (day 0) was 9.89% (Figures 2(c) and
2(d)). This percentage did not vary signiﬁcantly after vaccin-
ation or boost vaccination. It increased from day 57, nine
days after challenge, and peaked between days 62 and 68.4 The Scientiﬁc World Journal
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Figure 2: Mean percentages (± SD) and individual percentages of PBMC populations labeled by antibodies against CD4+ (a, b), CD8+ (c,
d), and WC1+ (e, f) throughout the experiment. ∗ is statistically signiﬁcant diﬀerence (P ≤ 0.05) from prevaccination value on day 0, based
on ANOVA with the Huynh-Feldt correction. Abbreviations: V, day of ﬁrst vaccination; DFV, day after ﬁrst vaccination; BV, day of boost
vaccination; C, day of challenge.
3.4.3. WC1+. The percentage of γδ T lymphocytes labeled by
the anti-WC1+ antibody did not vary signiﬁcantly from the
prevaccination value of 14.28% (Figures 2(e) and 2(f)).
3.4.4. CD25+. The percentage of CD25+ cells increased sli-
ghtly, but not signiﬁcantly, from a pre-vaccination value of
7.44% to 14.18% on day 14 (Figure 3(a)). This percentage
did not change signiﬁcantly after boost vaccination. After
challenge, however, all ﬁve animals showed an increase in the
proportion of CD25+ cells. For example, by day 51, the level
in sheep 4 and sheep 5 had increased, respectively, to 24.2%
and 31.3% (Figure 3(b)). The level increased signiﬁcantlyThe Scientiﬁc World Journal 5
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Figure 3: Mean percentages (± SD) and individual percentages of PBMC populations labeled by antibodies against CD25+ (a, b), B+ cells
(c, d), and CD14+ (e, f) throughout the experiment. ∗is statistically signiﬁcant diﬀerence (P ≤ 0.05) from the mean pre-vaccination value
on day 0, based on ANOVA with the Huynh-Feldt correction. Abbreviations: V, day of ﬁrst vaccination; DFV, day after ﬁrst vaccination; BV,
day of boost vaccination; C, day of challenge.
again between days 54 and 57, peaking on day 54 (31.2%).
Subsequently, the level decreased progressively and returned
to pre-vaccination values at the end of the experiment.
3.4.5. B Lymphocytes. The percentage of B cells decreased
signiﬁcantly after vaccination, with the lowest level of 15.4%
occurringonday14(Figures3(c)and3(d)).Thelevelsigniﬁ-
cantlyincreasedthereafterbetweendays16and21,andagain
after boost vaccination between days 35 and 48. After chal-
lenge,thepercentagevariedslightly,showingasigniﬁcantin-
crease on day 58.
3.4.6. CD14+. The percentage of monocytes labeled by the
anti-CD14+ antibody did not change signiﬁcantly from its6 The Scientiﬁc World Journal
pre-vaccination value of 3.85% after vaccination or boost
vaccination(Figures3(e)and3(f)).Afterchallenge,however,
the percentage increased signiﬁcantly, reaching 10.28% on
day 57. Subsequently, it decreased until it returned to pre-
vaccination values on days 62 and 68. After challenge, all ani-
malsshowedan increasefollowedbyamarked decrease.This
response occurred on diﬀerent dates for diﬀerent animals,
though in all cases the levels reached similar values.
4. Discussion
The inactivated vaccine against BTV serotype 1 (Zulvac1,
FortDodgeVeterinariaSA)inducedaneﬀectiveimmuneres-
ponse in all vaccinated sheep. Challenge virus was not de-
tected in blood by RT-PCR even at 20 days after inoculation.
Except for a temperature increase observed in most animals
after the vaccination and boost vaccination, no clinical signs
or lesions characteristic of BTV infection were observed.
The temperature increase observed in most animals after
vaccination and boost vaccination may reﬂect activation/
stimulation of the immune system. Similar increases were
observed after administration of inactivated vaccines against
diﬀerent serotypes of BTV [23, 24]. However, such a temper-
ature increase was not observed in sheep after vaccination
or revaccination with vaccines containing virus-like particles
[25]. These vaccines lack genetic material and so are nonre-
plicative; instead, they contain complexes of structural pro-
teins(VP2,VP3,VP5,andVP7)[26].Therefore,eventhough
inactivatedBTVvaccinesdonotcontainlivevirus,theyseem
tohaveagreaterabilitytostimulatetheimmunesystemfrom
a very early stage due to the presence of potent adjuvants.
After subcutaneous administration of inactivated vac-
cines against BTV, the presence of viral RNA in blood should
not be detected [11, 27]. Moreover, such vaccines prevent
viral replication after challenge with homologous virus [28,
29]. Our results showed the absence of virus in blood after
both vaccinations as well as after challenge with BTV sero-
type 1. These ﬁndings suggest that this vaccine may prevent
both virus dissemination and disease spread from vaccinated
animals. Therefore, in the presence of vector-borne BTV
serotype1,theinactivatedvaccinenotonlypreventsvirusre-
plication but also eﬀectively induces a protective immune
response. The speciﬁc protection conferred by these vaccines
appears to relate to the key role played by structural pro-
tein VP2 in stimulating protective immunity mediated by T
and B cells [18, 30]. However, the immunological mecha-
nisms behind the protection observed in vaccinated animals,
including the possible role of the cellular immune response,
remains unclear.
At 14 days after vaccination, a speciﬁc antibody response
against BTV was observed in all vaccinated sheep, and it per-
sisted through the end of the experiment. This antibody res-
ponse was shown to be the main factor in protecting sheep
against BTV serotype 1. Our results are in agreement with
previous studies [8, 11], wherein the speciﬁc antibodies
detected by ELISA after administration of inactivated BTV
vaccines in sheep were considered to be neutralizing anti-
bodies with the ability to protect against the virus. Never-
theless, how antibodies against BTV neutralize virus in vivo
remains unclear, despite attempts to demonstrate antibody-
dependent cellular cytotoxicity [17, 31].
The potential role of the cellular immune response dur-
ing BTV infection and after vaccination is not fully under-
stood [4, 18, 20, 32]. In the present study, the speciﬁc anti-
body response detected in sheep after vaccination and boost
vaccination against BTV serotype 1 was not associated with
either a signiﬁcant increase in T lymphocyte subpopulations
(CD4+,C D 8 +,a n dW C 1 +)o ri nC D 2 5 + regulatory cells.
Moreover, signiﬁcant changes in the percentage of CD14+
monocyteswerenotobserved.Theseresultsareinagreement
with previous studies of inactivated vaccines against BTV
serotype 1 in sheep [33].
Thelackofcell-mediatedimmunityaftervaccinationand
boost vaccination in our experiment could be attributed to
diﬀerent components of the vaccine, in which inactivated
virus was mixed with an aluminum-based adjuvant. These
adjuvants delay the elimination of antigens after vaccine
administration, prolonging the antigenic stimulus. These
adjuvants also promote antibody response, even though
they have little stimulatory eﬀect on cell-mediated responses
[34–36]. This inability to stimulate a strong cell-mediated
response, together with the diversity of responses by antigen-
presenting cells following exposure to live or killed viruses
in vaccines [37, 38], may explain the moderate participation
of cell-mediated response after vaccination and boost vacci-
nation, as well as the absence of signiﬁcant changes in the
proportions of these immune cell populations.
On the other hand, B cells can recognize most antigens
without prior processing, and certain antigens can provoke
antibody formation in the absence of helper T cells, provid-
ingsuﬃcientsignalforBcellproliferationanddiﬀerentiation
into antibody-producing plasma cells [39, 40]. This may ex-
plain why the signiﬁcant increase in B lymphocytes observed
after vaccination and boost vaccination in the present study
was associated with an increase in speciﬁc antibodies against
BTV serotype 1.
After challenge, viral genome was not detected in vac-
cinated sheep, conﬁrming speciﬁc protection induced by
antibody response. In fact, antibody response after challenge
wassigniﬁcantlyhigherthanafterboostvaccination,andthis
increase was associated with a signiﬁcant increase in CD14+
monocytes, CD25+ cells, B lymphocytes, and CD8+ Tl y m -
phocytes. Thus, challenge with BTV serotype 1 signiﬁcantly
increased the levels of CD14+ monocytes and CD25+ regu-
latory cells. CD14 has been deﬁned as a central molecule in
antigen recognition and cellular interactions, where it plays a
key role in monocyte-mediated T-cell activation [18, 41]. In
addition to dendritic cells [32], monocyte macrophages play
an important role in antigen presentation and virus spread
during BTV infection [42, 43]. CD25 has been deﬁned as a
low-aﬃnity receptor for IL-2 that is expressed mainly on T
cells activated by interaction with antigens [44, 45]. Thus,
the increase in CD14+ monocytes and CD25+ regulatory
cells observed after challenge with BTV serotype 1 may
costimulate B cells, allowing their activation, proliferation,
and diﬀerentiation into antibody-producing plasma cells.The Scientiﬁc World Journal 7
Finally, after challenge with BTV serotype 1, an increase
in CD8+ T lymphocytes was observed, which became signif-
icant toward the end of the trial. Similar increases in CD8+
T lymphocytes and the cytokine IL-2 in association with an
increase in CD25 expression have been described after chal-
lenge of sheep vaccinated against BTV serotype 1 [33]. Such
increaseshave also been observed during experimental infec-
tions [31, 32, 46]. Thus, the activation and proliferation of
CD8+ T lymphocytes, which play a key role in the Th1 res-
ponse dominated by cytotoxic T cells, may also be associated
with the increase in CD14+ monocytes and CD25+ regula-
tory cells observed after challenge.
5. Conclusions
Collectively, these results demonstrate that a speciﬁc and
protective antibody response was induced after vaccination
and boost vaccination of sheep with an inactivated vaccine
against BTV serotype 1 (Zulvac1, Fort Dodge Veterinaria
SA). This response was associated with a signiﬁcant increase
in B lymphocytes. However, signiﬁcant increases were not
observed in T lymphocyte subpopulations (CD4+,C D 8 +,
and WC1+), CD25+ regulatory cells, or CD14+ monocytes.
After challenge with BTV serotype 1, antibody response sig-
niﬁcantly increased over the level observed after boost vac-
cination, and this was associated with signiﬁcant increases in
B lymphocytes, CD14+ monocytes, CD25+ regulatory cells,
and CD8+ cytotoxic T lymphocytes.
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